The institutional cluster is a modest positive signal but is dominated by passive rebalancers and lacks insider confirmation. The massive S-3 resale overhang (77.9M shares, >170% of outstanding) likely caps upside. Monitor for insider buying or a catalyst (e.g., ROBBIN trial data) to confirm the thesis before acting.
AGEN drugs
AGEN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 12 $6.90entry
- T+1 · 3mo ago +1.45%α +0.75% · $7.00
- T+5 · 3mo ago +19.71%α +20.15% · $8.26
- T+20 · 2mo ago −0.14%α +1.75% · $6.89
- T+60 · 12d ago +1.01%α +5.89% · $6.97
How similar events traded
Executive Summary
Five institutional investors, led by BlackRock and Geode, doubled their AGEN positions in Q2 2026, adding a net $8.9M to holdings totaling $12.4M. The cluster follows a Q2 earnings beat (revenue +34% YoY) but is dominated by passive/index funds and lacks insider corroboration, weakening the signal. The massive overhang from the recent S-3 resale registration (77.9M shares, >170% of outstanding) tempers the bullish read from institutional accumulation.
Key Financial Metrics
Institutional Positions
Net institutional flow: $8.9M
▲ Buyers (5)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| BlackRock | DOUBLED | +370% | $7.8M | $6.0M |
| Geode | DOUBLED | +197.1% | $3.2M | $2.0M |
| State Street | DOUBLED | +164% | $1.3M | $740.0K |
Key Facts
- 5 institutional buyers added $8.9M net in Q2 2026, with 0 sellers
- BlackRock doubled its stake to $7.8M (2.56M shares), the largest buyer
- All 5 buyers are mega-passive or asset managers, no activist or high-alpha hedge funds
- No insider open-market buying in the window (confluence score 33/100, institutions-only)
- Q2 2026 revenue beat (+34% YoY to $34.5M) but was largely non-cash royalty revenue
- S-3 filed 5 days ago registers 77.9M shares for resale, creating >170% overhang
Financial Impact
5 institutions accumulated $8.9M in new AGEN positions (total $12.4M), with BlackRock adding $6.0M alone
Risk Factors
- S-3 resale overhang of 77.9M shares could flood the market
- No insider buying to corroborate institutional conviction
- Q2 revenue beat was largely non-cash royalty revenue, not operational cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-AGEN-2026-Q2 |
Track record
12 reports on AGEN
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Viewing Entry $6.90 to $6.97 ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers